TRUIST FINANCIAL CORP

TFC-PR

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$2.0M

1 fund

Feb 17, 2026

$660K

1 fund

-66% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 13,418Value: $660K

**Signal Note: Driehaus Capital Initiates TFC-PR Position** This $660K position in Truist Financial's preferred shares is a portfolio diversification move by a growth-focused biotech allocator, not a biotech investment signal. TFC-PR offers fixed income characteristics (preferred equity) misaligned with Driehaus's typical growth equity strategy, suggesting either tactical cash management or balance sheet optimization rather than conviction on financial services or healthcare trends.

Eventide Asset ManagementNEWFeb 13, 2026

More TFC-PR Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AXON2 funds NVDA2 funds VEEV2 funds VCYT2 funds LBRT2 funds RMBS2 funds UNP2 funds LITE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note:** Eventide's initiation of a $2.0M position in TFC-PR (Truist Financial preferred shares) appears tangential to core biotech exposure and suggests portfolio diversification into fixed-income instruments rather than a biotech-specific catalyst. This move is inconsistent with Eventide's biotech-focused mandate and likely reflects opportunistic yield capture in preferred equity rather than company-specific pharmaceutical or medical device developments.